These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
24. Staphylococcus aureus exfoliative toxins: how they cause disease. Plano LR J Invest Dermatol; 2004 May; 122(5):1070-7. PubMed ID: 15140205 [No Abstract] [Full Text] [Related]
25. Development and evaluation of detection systems for staphylococcal exfoliative toxin A responsible for scalded-skin syndrome. Ladhani S; Robbie S; Garratt RC; Chapple DS; Joannou CL; Evans RW J Clin Microbiol; 2001 Jun; 39(6):2050-4. PubMed ID: 11376033 [TBL] [Abstract][Full Text] [Related]
26. The epidermolytic toxin of Staphylococcus aureus: its failure to bind to cells and its detection in blister fluids of patients with bullous impetigo. Baker DH; Dimond RL; Wuepper KD J Invest Dermatol; 1978 Oct; 71(4):274-5. PubMed ID: 701847 [TBL] [Abstract][Full Text] [Related]
27. Identification of a novel Staphylococcus pseudintermedius exfoliative toxin gene and its prevalence in isolates from canines with pyoderma and healthy dogs. Iyori K; Hisatsune J; Kawakami T; Shibata S; Murayama N; Ide K; Nagata M; Fukata T; Iwasaki T; Oshima K; Hattori M; Sugai M; Nishifuji K FEMS Microbiol Lett; 2010 Nov; 312(2):169-75. PubMed ID: 20875053 [TBL] [Abstract][Full Text] [Related]
32. [Isolation and purification of biologically active substances from Staphylococcus aureus isolated from a skin disease. II. Isolation and purification of exfoliative toxin]. Sugai M Hiroshima Daigaku Shigaku Zasshi; 1987 Dec; 19(2):402-8. PubMed ID: 3504874 [No Abstract] [Full Text] [Related]
33. Regulatory mechanism for exfoliative toxin production in Staphylococcus aureus. Kato F; Kadomoto N; Iwamoto Y; Bunai K; Komatsuzawa H; Sugai M Infect Immun; 2011 Apr; 79(4):1660-70. PubMed ID: 21282415 [TBL] [Abstract][Full Text] [Related]
35. Molecular mechanisms of blister formation in bullous impetigo and staphylococcal scalded skin syndrome. Hanakawa Y; Schechter NM; Lin C; Garza L; Li H; Yamaguchi T; Fudaba Y; Nishifuji K; Sugai M; Amagai M; Stanley JR J Clin Invest; 2002 Jul; 110(1):53-60. PubMed ID: 12093888 [TBL] [Abstract][Full Text] [Related]
36. Staphylococcal scalded skin syndrome. II. Serum level of anti exfoliatin and anti alpha-toxin in patients with staphylococcal scalded skin syndrome or bullous impetigo. Nishioka K; Nakano T; Hirao N; Teranishi H; Asada Y J Dermatol; 1977 Apr; 4(2):65-8. PubMed ID: 15461328 [TBL] [Abstract][Full Text] [Related]
37. [A case of staphylococcal scalded skin syndrome caused by exfoliative toxin-B producing MRSA]. Yokota S; Imagawa T; Katakura S; Mitsuda T; Arai K Kansenshogaku Zasshi; 1996 Feb; 70(2):206-10. PubMed ID: 8851394 [TBL] [Abstract][Full Text] [Related]
38. Current options for the treatment of impetigo in children. Sladden MJ; Johnston GA Expert Opin Pharmacother; 2005 Oct; 6(13):2245-56. PubMed ID: 16218885 [TBL] [Abstract][Full Text] [Related]
39. Staphylococcal scalded skin syndrome I. Purification of exfoliatin and maternal transmission of neutralizing ability against exfoliatin. Nishioka K; Nakano T; Hirao N; Asada Y J Dermatol; 1977 Feb; 4(1):13-8. PubMed ID: 16688917 [TBL] [Abstract][Full Text] [Related]
40. Recombinant Staphylococcus aureus exfoliative toxins are not bacterial superantigens. Plano LR; Gutman DM; Woischnik M; Collins CM Infect Immun; 2000 May; 68(5):3048-52. PubMed ID: 10769013 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]